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Overview of Cryptococcus
The infection caused  
by Cryptococcus “ 
is one of the most 
dangerous HIV-related 
issues…HIV therapy 
programs should not 
neglect  
to address this still  
lethal disease.” 
Vicent Esposito and Antonio 
Chirianni, HIV Therapy 2010
What is Cryptococcus?
Cryptococcus is a fungus, found in the soil, which 
produces spores that can be inhaled. If a person’s 
immune system is weakened (for example, by HIV), 
Cryptococcus can cause a life-threatening infection 
in the brain called cryptococcal meningitis. 
Why is Cryptococcus an important  
public health issue?
 • Cryptococcal infection is a leading cause of 
death among people living with HIV/AIDS.
 • Cryptococcus is the most common cause of 
adult meningitis in most of Africa. 
 • Death rates for patients diagnosed with 
cryptococcal meningitis are 30-70% in Africa 
and Asia.
 • Optimal medication to treat cryptococcal 
meningitis is often unavailable or very 
expensive.
 • Medical management of cryptococcal 
meningitis is intensive, requiring frequent 
lumbar punctures and lifelong medication. 
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Module 1: What is Cryptococcus?
Training objectives
 • Understand what Cryptococcus is and where it is found in the environment
 • Understand how Cryptococcus infects HIV/AIDS patients
 • Understand the high death rates associated with cryptococcal meningitis
 • Describe the global public health burden of cryptococcal meningitis
Supplies needed
 • Module 1 slides (optional)
What is Cryptococcus?
 • Cryptococcus is a fungus found in soil throughout the world.
 • Spores are inhaled from the environment by humans.
 • There is no person-to-person transmission of Cryptococcus.
Cryptococcal infection
 • After inhalation, the fungus can cause an acute lung infection, or, more frequently, 
cause no symptoms at all.
 • The fungus may stay dormant in the body for months to years. 
 • Reactivation of infection can occur in immunosuppressed people, such HIV/AIDS 
patients. 
 • Adult HIV/AIDS patients with a CD4 count < 100 are at highest risk for reactivation.
 • When Cryptococcus reactivates in the body, it can cause disease in the brain, lungs, skin, 
and bones. 
 • Meningitis (inflammation of the tissue surrounding the brain) is the most common 
form of cryptococcal disease in HIV/AIDS patients. 
 • Encephalitis (infection of the brain itself ) can also occur together with meningitis.
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Module 1: What is Cryptococcus?
Death from cryptococcal meningitis
 • Cryptococcal meningitis is a common cause of death among HIV/AIDS patients.
 • Even when patients are treated with anti-retroviral medications and anti-fungal therapy, 
30%-70% die from their cryptococcal infection.
 • In areas of the world where cryptococcal infection is common, it is estimated to cause as 
many deaths as tuberculosis.
Image courtesy of World Health Organization
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Module 1: What is Cryptococcus?
Globally, approximately 1 million new cases and 625,000 deaths 
occur per year from HIV-related cryptococcal meningitis.
Leading causes of death in sub-Saharan Africa, excluding HIV
Images adapted from B.J. Park et al. AIDS 2009; 23: 525-30.
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Module 1: What is Cryptococcus?
Discussion questions
 • Have you encountered many cases of cryptococcal meningitis while caring for 
patients?
 • Do you feel that you have enough knowledge to care for patients with 
cryptococcal disease?
 • Do you feel comfortable caring for patients with cryptococcal disease?
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Module 2: Recognizing Signs and 
Symptoms of Cryptococcal Disease
Training objectives
 • Identify the common signs and symptoms of cryptococcal meningitis
 • Recognize other clinical presentations of cryptococcal disease
 • Identify other diseases that may look like cryptococcal meningitis in HIV/AIDS 
patients
Supplies needed
 • Module 2 slides (optional)
Cryptococcal disease
 • After inhalation, the fungus can cause an acute lung infection, or, more frequently, cause 
no symptoms at all.
 • When Cryptococcus reactivates in the body, it can cause disease in the brain, lungs, skin, 
and bones. 
 • In the brain, Cryptococcus causes meningitis (inflammation of the tissue surrounding the 
brain).
 • Meningitis is the most common form of cryptococcal disease in HIV/AIDS patients. 
 • Cryptococcal disease should be suspected in any patient presenting with meningitis. It 
should be suspected in an HIV-infected patient who presents with symptoms consistent 
with meningitis, such as headache or confusion.
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Clinical course of cryptococcal disease
No symptoms or 
symptoms of  lung 
infection
Infection spreads





 • Confusion or coma
 • Neck stiffness
 • Sensitivity to light
 • Nausea, vomiting
Signs and symptoms of cryptococcal meningitis may include:
Symptoms
 • Change in mental status (ranging from confusion to lethargy to coma)
 • Headache
 • Nausea with or without vomiting




 • Cranial nerve palsies (e.g., eye movement problems)
Many of these signs/symptoms are due to inflammation of the meninges (the membranes 
that protect the brain and spinal cord) or increased intracranial pressure (elevated pressures in 
the brain).
Module 2: Recognizing Signs and 
Symptoms of Cryptococcal Disease
Meningitis
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Other clinical presentations of cryptococcal disease
 • Lung: Ranges from mild pneumonia to acute respiratory distress syndrome (ARDS); 
Shortness of breath, cough, and fever are the most common symptoms
 • Skin: Papules, pustules, nodules, ulcers are common skin lesions
 • Bone: Most commonly the vertebrae and ribs
Chest x-ray of cryptococcal infiltrate
Source: John Baddley
Cryptococcal skin lesion 
McCarthy et al 2007, South African Journal of HIV Medicine
Other diseases that may look like cryptococcal meningitis in persons  
with HIV/AIDS
 • TB meningitis is the most common
 • Meningoencephalitis caused by other organisms (mycobacterial, viral, bacterial, 
spirochetes, other)
 • Space-occupying lesions (lymphoma, Toxoplasma gondii, abscess, etc.)
 • HIV encephalopathy
 • Other conditions (toxic, metabolic, autoimmune, intracranial bleed, etc.)
Discussion questions
 • What signs and symptoms do your patients with cryptococcal disease usually have?
 • What diseases mimic or look like cryptococcal disease at your clinic?
Module 2: Recognizing Signs and 
Symptoms of Cryptococcal Disease
12 Cryptococcal Screening Program Training Manual
Module 3: Diagnosing Cryptococcal 
Disease
Training objectives
 • Describe the current methods used to diagnose Cryptococcus infection
 • Explain the new dipstick test and the characteristics of this test
 • Understand which test to use when diagnosing cryptococcal meningitis
 • Understand the role of lumbar puncture in diagnosing cryptococcal meningitis
Supplies needed
 • Module 3 slides (optional)
 • Cryptococcal lateral flow assay test kit (for demonstration)
Current diagnostic methods
There are several ways to detect Cryptococcus spp. infections. Traditional methods include 
observation of the organism with a microscope, and growth of the organism in culture. 
Observation using microscopy requires a special but simple stain called India Ink. Both 
microscopy and culture are accurate methods to detect cryptococcal organisms, but they are 
not very sensitive (in a small number of cases they may not detect the organism even if it is 
present in the body, leading to a missed diagnosis). In addition, culture results may take days 
to weeks to obtain the final results.
India Ink microscopy  Culture
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Module 3: Diagnosing Cryptococcal 
Disease
Cryptococcal antigen, a chemical marker for infection, is produced by the fungus 
Cryptococcus. Traditional tests that detect cryptococcal antigen (latex agglutination and 
enzyme immunoassay) are both sensitive and accurate, but are not always available. A new 
antigen detection test, called the Lateral Flow Assay (LFA), is a rapid dipstick test. The test 
cannot be used to monitor clinical response to treatment, because serum (a component 
of blood) may remain positive for cryptococcal antigen for days to months after successful 
treatment. Antigen can also be detected in cerebrospinal fluid (CSF) and serum weeks to 
months before meningitis symptoms develop.
Method Usual Specimen type
India Ink microscopy CSF (Cerebrospinal fluid)
Culture CSF, blood, or appropriate tissue
Antigen detection 
• Latex agglutination (LA) 
• Enzyme immunoassay (EIA) 
• Lateral flow assay (LFA)
 
CSF or serum 
CSF or serum 
CSF or serum
Dipstick test The new lateral flow assay (LFA) is…
 • Effective: The test is sensitive, accurate (>95%), and 
highly predictive of who is at risk for developing 
cryptococcal meningitis. 
 • Simple and quick: The results of the LFA are available 
in 10 minutes. 
 • Affordable (approximately $2-4 per test)
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How to diagnose  
cryptococcal meningitis
Patients with signs or symptoms of 
meningitis and patients with evidence 
of cryptococcal disease anywhere in 
the body need to be evaluated for 
cryptococcal meningitis. To diagnose 
cryptococcal meningitis, it is necessary 
to examine the cerebrospinal fluid 
(CSF) around the brain. CSF is collected 
by performing a procedure called a 
lumbar puncture, in which a needle 
is put into the patient’s back and a 
small amount of CSF is removed from 
the spinal column. This procedure 
should only be performed by trained 
physicians.
Three tests should be performed on 
CSF to detect Cryptococcus: (1) India 
Ink stain, (2) a cryptococcal antigen 
detection test, and (3) fungal culture. 
At least one of these tests should 
be positive in order to confirm the 
diagnosis of cryptococcal meningitis.  
Other CSF tests (see next section) 
will help you determine whether 
the patient’s symptoms are due to 
Cryptococcus or other organisms.
CSF surrounds 
the brain and 
spinal cord




to remove a 
small sample 
of spinal fluid.
Module 3: Diagnosing Cryptococcal 
Disease
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Module 3: Diagnosing Cryptococcal 
Disease
Performing a lumbar puncture (for trained physicians only)
Lumbar puncture is important for both diagnosis and treatment of CM.  A lumbar puncture 
is required to obtain CSF to establish a diagnosis of cryptococcal meningitis. It is also used 
to measure intracranial pressure and to remove CSF in patients with elevated intracranial 
pressure.
Before performing a lumbar puncture, you should ensure that there are no focal neurologic 
deficits. If there are, perform a head CT first to rule out a space-occupying lesion. In resource-
limited settings where CT scans are not available, you may consider proceeding without 
imaging, but this decision should be discussed with a senior clinician, weighing potential risks 
and benefits.
When performing a lumbar puncture, always record the opening pressure (normal: <20 cm). 
When evaluating a patient for cryptococcal meningitis, request the following: microscopy (cell 
count, Gram stain, India Ink stain), chemistry (protein, glucose), bacterial culture, and tests 
for Cryptococcus (cryptococcal antigen, fungal culture). To rule out other common causes of 
meningitis in HIV/AIDS patients, consider ordering adenine deaminase and mycobacterial 
smear and culture (tuberculosis), TPHA or FTA (syphilitic meningitis), and Toxoplasma 
antibodies (toxoplasmosis).
How to diagnose non-meningeal cryptococcal disease
If non-meningeal cryptococcal disease is suspected, an antigen detection test, India Ink 
stain, or culture of the relevant clinical specimen may be useful (for example, a skin biopsy 
or sputum sample). Any patient with a positive test needs to be evaluated with a lumbar 
puncture for cryptococcal meningitis.
Discussion questions
 • What kind of test do you currently use/order when you suspect cryptococcal disease?
 • Is lumbar puncture currently available where you care for patients?
 • How often do your patients refuse a lumbar puncture?
 • What challenges do you encounter if you have to refer patients to another facility for 
lumbar puncture?
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Module 4: Treating Cryptococcal 
Meningitis
Training objectives
 • Describe the current treatment for adult cryptococcal meningitis
 • Understand the importance of managing intracranial pressure
 • Describe common side effects from fluconazole therapy
 • Describe other uses of fluconazole
 • Describe important fluconazole drug interactions
 • Define immune reconstitution inflammatory syndrome (IRIS)
Supplies needed
 • Module 4 slides (optional)
Treatment of adult cryptococcal meningitis
Treatment of cryptococcal meningitis consists of three phases: induction, consolidation, and 
maintenance. Induction is given to rapidly clear the organism from the body. Consolidation 
is given to ensure that the organism is completely eradicated. Maintenance is given to prevent 
recurrence of disease after treatment; this phase is also known as secondary prophylaxis.
Induction phase Consolidation phase Maintenance Phase
2 weeks 8 weeks 
Begin ART after 2 weeks of 
consolidation therapy
1 year on ART and CD4 ≥ 200 if viral 
load monitoring not available, or CD4 ≥ 
100 and a suppressed viral load.
Amphotericin B is an intravenous medication that is given only in hospitals as it requires 
close monitoring for side effects. Fluconazole is an oral medication that is available in some 
areas of the world free of cost through the Diflucan Partnership Program (Pfizer). The World 
Health Organization (WHO) guidelines on the “Diagnosis, Prevention, and Management of 
Cryptococcal Disease in HIV-Infected Adults, Adolescents, and Children” (2011) recommend 
the treatment regimen described on the following page for adults (see table on following 
page). For patients receiving amphotericin B, WHO’s minimum toxicity prevention, monitoring, 
and management regimen is also presented on the following page. If viral load monitoring 
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Module 4: Treating Cryptococcal 
Meningitis
is not available, maintenance treatment for cryptococcal meningitis should be given until 
the patient is stable and adherent to ART and anti-fungal maintenance for at least one 
year and has a CD4 count greater than or equal to 200. If viral load monitoring is available, 
maintenance treatment should be given until the patient is stable and adherent to ART and 
anti-fungal maintenance for at least one year, has a suppressed viral load, and has a CD4 























AmB ±  
flucytosine















AmB Not available 
for full 2-week 
induction 
period
AmB 0.7 -1 mg/
kg/day short 
course (5-7 days) 






AmB not  
available
Not available a.  Fluconazole 
1200 mg/day ± 
flucytosine 100 
mg/kg/day





World Health Organization (2011). “Rapid advice: Diagnosis, Prevention, and Management of Cryptococcal Disease in HIV-Infected Adults, 
Adolescents, and Children.
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Module 4: Treating Cryptococcal 
Meningitis
Minimum package for amphotericin B toxicity prevention, monitoring and management
Pre-emptive hydration and electrolyte supplementation
 • Adults: One liter of normal saline solution with one ampule (20 mmol) of KCL over 
2-4 hours before each controlled infusion of amphotericin B (with one liter of 5% 
dextrose) and one to two 8mEq KCL tablets orally twice daily. An additional one 8mEq 
KCL tablet twice daily may be added during the second week. If available, magnesium 
supplementation should also be provided (two 250mg tablets of magnesium trisilicate 
twice daily).
 • Adolescents and Children: Up to one liter of normal saline solution with one ampule 
(20 mmol) of KCL at 10-15 ml/kg over 2-4 hours before each controlled infusion of 
amphotericin B. If saline is unavailable, then other intravenous rehydration solutions that 
contain potassium can be used eg. Darrow’s or Ringer’s Lactate solutions.
 • Potassium replacement should not be given patients with pre-existing renal impairment 
or hyperkalemia.
 • A test dose for amphotericin B is not recommended.
Monitoring
 • Serum potassium and creatinine (baseline and twice weekly), especially in the second 
week of amphotericin B administration.
 • Hemoglobin (baseline and weekly).
 • Careful attention to fluid monitoring of intake and output, and daily weight.
Management
 • If significant hypokalemia (K <3.3mmol/l), increase potassium supplementation to two 
KCL ampules (40 mmol), or one or two 8mEq KCL tablets three times daily. Monitor 
potassium daily.
 • If hypokalemia remains uncorrected, double magnesium oral supplementation.
 • If creatinine increases by >2 fold from baseline value, either temporary omission of an 
amphotericin B dose, or increase pre-hydration to one liter 8 hourly. Once improved, 
restart at 0.7 mg/kg/day and consider alternate day amphotericin B. If creatinine remains 
elevated, discontinue amphotericin and continue with fluconazole at 1200 mg/day. 
Monitor creatinine daily.
World Health Organization (2011)
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Managing intracranial pressure (for trained physicians only)
Intracranial pressure (ICP) is elevated in most patients with cryptococcal meningitis and, if 
left untreated, can lead to death. Managing ICP is an important part of caring for patients 
with cryptococcal meningitis. ICP should be measured at the time of lumbar puncture using 
a manometer (see picture below). Physicians should refer to the following Infectious Diseases 
Society of America (IDSA) 2010 guidelines for managing elevated ICP: “If the CSF pressure is 
≥25 cm of CSF and there are symptoms of increased intracranial pressure during induction 
therapy, relieve by CSF drainage (by lumbar puncture, reduce the opening pressure by 50% 
if it is extremely high or to a normal pressure of ≤20 cm of CSF). If there is persistent pressure 
elevation >25 cm of CSF and symptoms [of meningitis], repeat lumbar puncture daily until 
the CSF pressure and symptoms have been stabilized for >2 days and consider temporary 
percutaneous lumbar drains or ventriculostomy for persons who require repeated daily 
lumbar punctures.” 
Module 4: Treating Cryptococcal 
Meningitis
General information about fluconazole 
(Diflucan)
Fluconazole (brand name Diflucan) is an oral anti-
fungal medication available in 50, 100, 150, or 200 mg 
tablets. It is usually taken in pill format but can also 
be taken as an oral suspension. Fluconazole can be 
taken with or without food and can be taken at any 
time of day.
Indications for fluconazole use
Fluconazole can be used as treatment or prophylaxis 
for a variety of systemic and superficial fungal 
infections. In addition to treating cryptococcosis, 
fluconazole is also commonly used to treat 
candidiasis of the vagina, esophagus, and mouth/ 
throat (also called “oropharyngeal candidiasis” or 
“thrush”). 
Measurement of CSF opening  
pressure using manometer.
Source: McCarthy et al 2007, South African 
 Journal of HIV Medicine
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Module 4: Treating Cryptococcal 
Meningitis
Side effects of fluconazole therapy
Fluconazole is an oral medication with several possible side effects including:
 • Diarrhea, nausea, abdominal pain
 • Headache, dizziness
 • Rash
 • Liver toxicity
 • Teratogenicity (can cause damage to fetus, especially during the 1st trimester)
Fluconazole drug interactions
Fluconazole can interact with other medications, including some drugs used to treat HIV/
AIDS and tuberculosis. These include nevirapine (an anti-retroviral drug) and rifampicin (a 
tuberculosis drug). Patients on nevirapine should be monitored closely for signs of liver 
toxicity because combination use with fluconazole increases nevirapine levels. Concomitant 
use of rifampicin and fluconazole decreases levels of fluconazole in the blood.
The Diflucan Partnership Program (DPP)
Since 2000, Pfizer has provided fluconazole for the treatment of two major opportunistic 
fungal infections associated with HIV/AIDS: esophageal candidiasis and cryptococcal 
meningitis.  Through the Diflucan Partnership Program, fluconazole is available free of cost to 
government and nongovernmental organizations in certain resource-limited countries where 
the prevalence of HIV/AIDS is greater than 1%. 
More information about the DPP is available on the web at:  
http://www.directrelief.org/DiflucanPartnership/EN/DiflucanProgramOverview.aspx
Side effects of amphotericin B therapy
Amphotericin B is an intravenous medication with many potentially serious side effects. It 
should only be given in settings where side effects and response to therapy can be closely 
monitored. Serious side effects of amphotericin B therapy include acute infusion reactions, 
renal toxicity, and electrolyte abnormalities.
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Module 4: Treating Cryptococcal 
Meningitis
Immune reconstitution inflammatory syndrome (IRIS)
Some patients with HIV/AIDS can actually get sicker after they start anti-retroviral treatment 
(ART). Clinical worsening or new presentation of cryptococcal disease after starting ART is 
called cryptococcal immune reconstitution inflammatory syndrome (IRIS). There are two types 
of IRIS: unmasking and paradoxical. Unmasking IRIS refers to a new diagnosis of cryptococcal 
disease after ART is started. Paradoxical IRIS refers to worsening of known existing 
cryptococcal disease or recurrence of previously treated cryptococcal disease. IRIS generally 
occurs in the first weeks to months after ART is started, but can occasionally occur later. 
Because IRIS can be life-threatening, it is currently recommended that ART-naïve patients 
diagnosed with cryptococcal meningitis should receive some anti-fungal therapy before 
ART is started.  According to WHO, ART initiation should be delayed until there is evidence of 
clinical response to anti-fungal therapy and induction and consolidation treatment has been 
given:
 • For meningeal disease: 
 » If the patient received amphotericin B, begin ART after 2-4 weeks
 » If the patient received high-dose fluconazole, begin ART after 4-6 weeks
 • For non-meningeal disease: 
 » If the patient received amphotericin B, begin ART after 2 weeks
 » If the patient received high-dose fluconazole, begin ART after 4 weeks
Discussion questions
 • Is amphotericin B generally available for patients with cryptococcal meningitis?
 • Are you able to prescribe fluconazole? 
 • What are the barriers to prescribing fluconazole in your setting?
 • Are patients able to get fluconazole free of cost by using the Diflucan Partnership 
Program?
 • What side effects have patients taking fluconazole had?
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Module 5: Preventing Cryptococcal 
Meningitis
Training objectives
 • Describe the importance of preventing cryptococcal meningitis
 • Understand the advantages and disadvantages of primary prophylaxis
 • Describe the rationale behind cryptococcal screening
Supplies needed
 • Module 5 slides (optional)
Why is preventing cryptococcal meningitis important?
As you learned in Module 1, cryptococcal disease is common among HIV/AIDS patients and is 
responsible for a large number of deaths in this population, especially among those with CD4 
<100. In resource-limited settings, a lack of diagnostic tools can lead to a delay in identifying 
cryptococcal meningitis, and anti-fungal therapy is often costly or not available at all. Even 
when anti-fungal therapy is given, patients who already have cryptococcal meningitis often 
do poorly because they are diagnosed late in the course of disease. Patients are most at risk 
for getting sick from Cryptococcus before they start ART (when their CD4 counts are low) 
and immediately after starting ART (due to cryptococcal IRIS). Cryptococcal meningitis may 
account for 20% of early deaths among patients starting ART.
Primary prophylaxis
One strategy to prevent cryptococcal meningitis deaths is to treat all HIV/AIDS patients with 
a CD4 <100 with low-dose fluconazole, such as 200 mg daily. This strategy has been shown 
to decrease the number of cryptococcal infections, but has not consistently been shown 
to decrease rates of death from cryptococcal disease. There are several concerns about 
widespread use of fluconazole including cost, drug resistance, drug adverse events, and safety 
in vulnerable populations (pregnant women and patients with liver disease). 
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Module 5: Preventing Cryptococcal 
Meningitis
Cryptococcal screening
Cryptococcal screening is another strategy to prevent deaths from cryptococcal meningitis.
Cryptococcal antigen (a chemical marker that is found in people with active disease) can be 
detected in the blood weeks to months before the patient develops symptoms of disease. 
Patients who are found to have cryptococcal antigen in their body are much more likely 
to develop meningitis than those who do not have antigen. The presence of cryptococcal 
antigen is highly predictive for the development of cryptococcosis. 
Instead of treating everyone with a CD4 count < 100 (primary prophylaxis), patients with 
low CD4 counts can be screened for cryptococcal antigen in their blood, and treated 
with fluconazole only if they test positive. The benefit of this strategy is that it minimizes 
unnecessary treatment of patients who are at lower risk of getting sick from Cryptococcus. 
This decreases costs and concerns about drug resistance, side effects, and safety.
+Serum 





 • What infections common among HIV/AIDS patients do you currently give primary 
prophylaxis medications for?
 • What other infections common among HIV/AIDS patients do you currently screen for?
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Module 6: Decision-Making Guide 
for Cryptococcal Screening
Training objectives
 • Use the decision-making guide to manage an adult patient with a positive 
screening cryptococcal antigen test
 • Understand how cryptococcal screening fits into routine HIV care
Supplies needed
 • Module 6 slides (optional)
Cryptococcal screening principles
1. Identify patients at risk (CD4 less than 100)
2. Test for cryptococcal antigen before onset of meningitis symptoms
3. Treat with oral fluconazole
4. Prevent cryptococcal meningitis deaths
Decision-making guide
When you order a CD4 count test, the laboratory will automatically perform a cryptococcal 
antigen test on all patients whose CD4 count is <100. A patient with a positive cryptococcal 
antigen test should be contacted urgently to return to the clinic for follow-up, so it is 
important to keep a detailed record of patients’ contact information. The patient should be 
assessed for symptoms of meningitis and for special situations (see decision-making guide on 
the following page). If the patient has any symptom of meningitis (headache lasting longer 
than 24 hours, fever, confusion or coma, blurry vision, or neck stiffness), he or she will need a 
lumbar puncture. Patients with a lumbar puncture that shows Cryptococcus in the spinal fluid 
will need to be hospitalized for two weeks of amphotericin B therapy (refer back to the WHO 
guidelines on page 16 of this training manual). 
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Reflex cryptococcal antigen screening 
CD4<100 specimens
Contact patient for urgent follow-up  
Screen for symptoms of meningitis
Symptomatic Asymptomatic† *
Lumbar puncture
Treat with fluconazole, at least 800 mg 




Initiate ART* after 2 weeks of therapy
Fluconazole 400 mg daily for 8 weeks, then 






Module 6: Decision-Making Guide 
for Cryptococcal Screening
If the patient does not have any symptoms of meningitis at the time of the clinic visit or if 
the lumbar puncture is negative for Cryptococcus in the CSF, the patient should be started 
on fluconazole as outlined in the decision-making guide for cryptococcal screening for your 
country or the recommendations in the WHO guidelines (Module 4). Patients who develop 
meningitis symptoms despite fluconazole treatment need to undergo a lumbar puncture.
CNS Disease
This flowchart describes clinical decision-making steps that should 
occur based on the results of a patient’s cryptococcal antigen 
(CrAg) test. When a CD4 count test is ordered, the laboratory will 
automatically perform a CrAg test on all patients whose CD4 
count is below 100. A patient with a negative CrAg test can begin 
antiretroviral treatment (ART) immediately. A patient with a positive 
CrAg test should be contacted to return to the clinic for a follow-up 
visit. The patient then should be assessed for symptoms of meningitis 
and for other conditions, which are described on the following page. 
If the patient has any symptom of meningitis (headache lasting 
longer than 24 hours, fever, confusion or coma, blurry vision, or 
neck stiffness), he or she will need a lumbar puncture. Patients with 
a lumbar puncture that shows Cryptococcus in the spinal fluid will 
need to be hospitalized for two weeks of amphotericin B therapy. If 
the patient does not have any symptoms of meningitis at the time of 
the clinic visit, or if the lumbar puncture is negative for Cryptococcus 
in the spinal fluid, the patient should be treated with fluconazole, 
at least 800 mg daily for two weeks. After completing two weeks of 
treatment with either amphotericin B or 800 mg of fluconazole, all 
patients can begin ART. Fluconazole 400 mg daily should be given 
for 8 weeks, followed by 200 mg daily until the patient’s CD4 count is 
greater than 200 for at least 6 months on ART.
† If resources are available, a lumbar puncture should also be offered to asymptomatic patients with appropriate 
counseling. 
*Populations who require special attention include: patients on tuberculosis medications or nevirapine, patients 
with a previous history of cryptococcal meningitis, pregnant women or breastfeeding mothers, patients with 
liver disease, and children.
**Initiate ART if not already started
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Module 6: Decision-Making Guide 
for Cryptococcal Screening
Other clinical conditions
Patients on tuberculosis medications
Tuberculosis medications (including INH) and fluconazole can be started at the same time. 
Because both fluconazole and TB medications can damage the liver, these patients should 
preferably be started on an efavirenz-based ART regimen. Patients should be monitored 
closely for signs of liver damage including right upper quadrant abdominal pain, nausea/
vomiting, or jaundice (yellowing of the skin and eyes). If there are signs of toxicity, then liver 
function tests should be ordered.
Patients on nevirapine 
For patients starting ART, use efavirenz-based regimen rather than nevirapine, since 
nevirapine might increase the risk of liver damage. If patient is already on nevirapine, then the 
patient should be monitored closely for signs of liver damage including right upper quadrant 
abdominal pain, nausea/vomiting, or jaundice (yellowing of the skin and eyes). If there are 
signs of toxicity, then liver function tests should be ordered.
Patients with previous history of cryptococcal meningitis 
Patients with a previous history of CM do not need to be routinely screened. However, if 
the patient has new symptoms of meningitis, he/ she will need to be evaluated for relapse 
disease and/or IRIS. If the patient does not have new symptoms, the health care provider 
should ensure that the patient has received or is receiving adequate maintenance therapy 
(fluconazole 200 mg until CD4 count >200 cells/µl on ART and for a minimum of 12 months 
total) after being treated with induction and consolidation therapy.  
Pregnancy or breastfeeding mothers
Because fluconazole can be harmful to a fetus, all women of childbearing age should have 
a pregnancy test. The risks, benefits and alternatives to fluconazole treatment should be 
discussed with the patient. Consultation with a physician experienced in the care of HIV/AIDS 
patients is recommended.  Mothers who are breastfeeding also require consultation with an 
experienced physician as fluconazole can be transmitted through breast milk to the infant. 
Women of childbearing age who are not yet pregnant and are starting fluconazole treatment 
should be advised to avoid becoming pregnant during treatment.
Liver disease 
Patients with history of liver disease (cirrhosis, hepatitis, etc.), jaundice (yellowing of the 
skin and eyes), or abnormal liver enzyme tests may deserve careful monitoring because 
fluconazole may cause liver damage. Consultation with a physician experienced in the care of 
HIV/AIDS patients is recommended.
Children 
Screening is not recommended for children as CM is less common in this group. All children 
who are serum CrAg-positive should be referred for lumbar puncture (LP). Children with a 
positive LP should be managed according to your country-specific guidelines or the WHO 
guidelines, available on page 25 of the document available at: http://whqlibdoc.who.int/
publications/2011/9789241502979_eng.pdf.
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Module 6: Decision-Making Guide 
for Cryptococcal Screening
What should I do if a lumbar puncture cannot be performed?
1. If a lumbar puncture is contraindicated but the patient is symptomatic and has a 
positive serum CrAg test, the patient should be treated with amphotericin B.
2. If a lumbar puncture cannot be performed because resources are not available, the 
patient should be transferred to the nearest facility where such services are available.
3. If a lumbar puncture cannot be performed because the patient refuses the procedure, 
every effort at proper patient education and discussion of risk and benefits should be 
made. If the patient still refuses, he or she will need to be treated like a patient for whom 
a lumbar puncture is contraindicated (see #1)
What should I do if amphotericin B therapy is not available?
If amphotericin B is not available or cannot be given safely, the patient should be transferred 
to a facility where amphotericin B is available. If the patient cannot be transferred, use of 
high-dose fluconazole (induction phase, fluconazole 1200 mg/day ± flucytosine 100 mg/
kg/day) may be considered in consultation with a physician experienced in HIV/AIDS care, 
however, this is not the recommended treatment  regimen. Amphotericin B should always be 
the drug of first choice as it clears Cryptococcus from the body much faster than fluconazole.
How does screening fit into routine HIV care?
Like co-trimoxazole prophylaxis and isoniazid preventive therapy (IPT), cryptococcal 
screening and treatment of antigenemia with oral fluconazole can be part of an integrated 
care and treatment strategy for HIV/AIDS patients. In areas where cryptococcal disease 
prevalence is high, an integrated approach can help reduce early mortality among HIV/AIDS 
patients starting ART.
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Start ART and continue fluconazole 400 
mg for a total of 2 months. Instruct 
 patient to decrease fluconazole to 200 
mg after 2 months.
Use Decision-Making Guide to 












ART Clinic Intake Visit
Baseline blood testing
Review CD4 testing results
Review cryptococcal test (if CD4<100)
Start Bactrim
Refer to counseling
When a patient presents for HIV testing 
and CD4 testing, he or she will also be 
screened for symptoms of tuberculosis 
(TB). If the patient has symptoms of TB, he 
or she will have laboratory tests performed 
to confirm the diagnosis, and should be 
prescribed appropriate medication. If 
the patient does not have symptoms of 
TB, he or she will be prescribed Isoniazid 
preventive therapy. At the patient’s ART 
intake clinic visit, the results of the CD4 
test will be reviewed along with the 
results of the cryptococcal antigen test, 
if the patient’s CD4 count was under 100. 
Patients with symptoms of cryptococcal 
meningitis should then be managed using 
the cryptococcal decision-making guide, 
and may require antifungal treatment 
before beginning ART. Patients without 
symptoms of cryptococcal meningitis can 
begin ART immediately.  
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Module 7: Your Role as a Health Care 
Provider
Training objectives
 • Understand what you can do as a health care provider as part of the screening 
program for cryptococcal antigen
 • Be able to counsel your patients on fluconazole adherence
Supplies needed
 • Module 7 slides (optional)
What you can do as a health care provider
 • Educate yourself on cryptococcal screening and preventive management of HIV/AIDS 
patients starting ART.
 • Save lives by screening your patients and treating them with oral fluconazole before 
symptoms of cryptococcal meningitis develop.
 • Counsel your patients on fluconazole adherence. 
 • Provide regular feedback to coordinators regarding the program’s operation so that they 
can make improvements.
 • Build awareness of cryptococcal meningitis by teaching other health care providers about 
this screening strategy.
How to counsel your patients 
First, patients should understand that cryptococcal antigenemia can be deadly if it is not 
treated. For this reason, you should emphasize the importance of taking fluconazole, even 
if the patient does not have any symptoms.  It is also important to make sure that patients 
understand how many fluconazole pills to take. 
Finally, encourage patients to contact the clinic immediately if they begin to experience 
side effects related to fluconazole therapy, which include diarrhea, nausea, abdominal pain, 
headache, dizziness, rash, or symptoms of liver toxicity.
Discussion questions
 • What difficulties do you anticipate having when screening patients for Cryptococcus? 
 • What difficulties do you anticipate with patients’ adherence to fluconazole?
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Case Studies
Image courtesy of World Health Organization
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Case Study 1: Symptomatic Presentation 
of Cryptococcal Meningitis
Highlights the typical presentation and basic management of cryptococcal meningitis 
Patient history and initial presentation
A 49 year-old, newly-diagnosed HIV-positive man is referred to your clinic with a CD4 count of 
9. He has been having watery diarrhea for 1 month, and has lost 10 kg over the past 2 months. 
He lives by himself and drinks 1 bottle of wine and 2 glasses of brandy per day.
He reports no headache, fever, confusion, neck stiffness, or sensitivity to light. However, he is 
very wasted, mildly dehydrated, and has oral candidiasis.
Patient management
Baseline bloods are ordered: full blood count, creatinine, ALT, and RPR 
Stool sample is collected and sent to the lab. 
Serum cryptococcal antigen (CrAg) test reviewed: positive 
The patient is told to complete readiness classes and return to the clinic in 2 weeks to begin 
ART
Medications prescribed 
Nystatin mouth wash 
Bactrim 2 tabs/day 
Vitamin B complex 2 tabs/day 
Thiamine 200 mg/day (in view of alcohol history and possible malabsorption) 
Vitamin C 100 mg/day
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Patient progress
The patient does not return to your clinic to start ART. Three months later, he presents to the 
hospital with a headache, neck stiffness, and confusion. A lumbar puncture shows that his 
intracranial pressure is very high (45 cm), and that his spinal fluid contains Cryptococcus (India 
Ink and CrAg positive). Daily therapeutic LPs are performed to reduce his intracranial pressure, 
and his creatinine, potassium, and magnesium are monitored.  He is started on amphotericin 
B with pre-hydration.
Patient progress
Despite appropriate management, the patient dies on day 5 of admission.
Discussion points
1. On his return visit, the patient had markers of severe cryptococcal meningitis: altered 
mental status and raised opening CSF pressure.
2. Although patients with low-level cryptococcal antigenemia may clear the infection 
with ART alone, many patients have a delay in starting ART (either due to other medical 
conditions such as TB or issues with access to care). This patient should have been 
prescribed fluconazole at his intake visit (followed by ART one to two weeks later) in 
order to prevent his silent cryptococcal infection from progressing to meningitis.
3. A delay in presentation can lead to severe meningitis with high mortality (up to 50%).
Case Study 1: Symptomatic Presentation 
of Cryptococcal Meningitis
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Case Study 2: Asymptomatic 
Presentation of Cryptococcal Meningitis
Highlights the potential treatment complications associated with cryptococcal meningitis
Patient history and initial presentation
A 40-year old man is referred to your clinic after a 2-week hospital stay with pneumocystis 
pneumonia, where he was treated with cotrimoxazole and steroids, and made a good 
recovery. He is newly diagnosed with HIV with a CD4 count of 11.  Upon presentation to the 
clinic, he has a headache, but no fever, confusion, or neck stiffness. However, he has severe 
oral candidiasis, one Kaposi’s sarcoma (KS) lesion on his back, and nerve pain in his feet.
Patient management
Baseline bloods are ordered: full blood count, creatinine, ALT, and RPR 
Serum cryptococcal antigen (CrAg) test reviewed: positive 
Lumbar puncture performed: CSF CrAg test positive, India Ink positive 
Patient admitted to hospital for management of cryptococcal meningitis
Medication prescribed
Amphotericin B 1 mg/kg/day with pre-hydration
Patient progress
On day 4 of hospital admission, the patient’s creatinine is too high, which means his kidneys 
are failing. He is given fluids and the dose of amphotericin B is lowered. On day 10, the 
amphotericin B causes him to develop thrombophlebitis (swelling in the veins due to blood 
clots) and has become anemic. He completes 14 days of amphotericin B and is discharged on 
fluconazole.
At his post-hospital discharge clinic visit, the patient is doing well and does not complain of 
headaches. 
He is continued on fluconazole 800 mg/day and is started on ART (AZT, 3TC, EVZ in view of his 
poor kidney function and peripheral neuropathy (nerve pain).
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Case Study 2: Asymptomatic 
Presentation of Cryptococcal Meningitis
Discussion points
1. Late-stage HIV patients often have multiple other conditions, so it is important to look 
for cryptococcal meningitis.
2. Amphotericin B can have serious side effects, including abnormal heart rhythms, kidney 
failure, low potassium, abdominal discomfort, infusion reactions, phlebitis, anemia, and 
low white blood cell count.
3. Fluconazole can interact with some ART medications, and this is an important 
consideration when starting ART. For patients starting ART, use efavirenz-based regimen 
rather than nevirapine, since nevirapine might increase the risk of liver damage. If the 
patient is already on nevirapine then he or she should be monitored closely for signs 
of liver damage including right upper quadrant abdominal pain, nausea/vomiting, or 
jaundice (yellowing of the skin and eyes). If there are signs of toxicity, liver function tests 
should be ordered.
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Case Study 3: Previous Cryptococcosis
Highlights the importance of determining whether the patient has a history of cryptococcal 
meningitis
Patient history and presentation
A 37 year-old woman comes to your clinic for the first time with a CD4 count of 19.  She 
recently moved to Cape Town from Queenstown, leaving behind her medications and transfer 
letter. She reports no headache, fever, confusion, or neck stiffness, and there are no positive 
findings upon examination. 
Patient management
Baseline bloods are ordered: full blood count, creatinine, ALT, and RPR 
Serum cryptococcal antigen (CrAg) test reviewed: positive 
The patient is told to complete readiness classes and return to the clinic in 2 weeks to begin 
ARTs.
Medication prescribed
Fluconazole 800 mg/day for 2 weeks 
Bactrim 2 tablets/day 
Vitamin B complex 2 tablets/day
Patient progress
At her follow-up visit, the patient is doing well. Her sister brought the patient’s original 
medications and clinic transfer letter. You learn that the patient had previously been admitted 
to hospital with cryptococcal meningitis 2 months ago, and was prescribed fluconazole 200 
mg/day, Bactrim, and Vitamin B complex.
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Case Study 3: Previous Cryptococcosis
Discussion Points
1. Cryptococcal antigen can be present for up to 2 years after an episode of cryptococcosis. 
A patient with previous cryptococcal disease and a positive screening test needs to be 
evaluated for symptoms of cryptococcal meningitis. 
2. A patient with previous cryptococcosis should remain on fluconazole prophylaxis 
until they have a CD4 count greater than 200 for at least 6 months on ART. If viral load 
testing is available, and the patient’s viral load is suppressed, he or she can discontinue 
fluconazole if his or her CD4 count is greater than 100 for at least 6 months on ART. 
3. Patients who have had previous cryptococcal disease are at risk of relapse of disease, 
especially if they have stopped taking their fluconazole prophylaxis. These patients are 
also at increased risk of cryptococcal Immune Reconstitution Inflammatory Syndrome 
(IRIS) when starting ART. 
4. Any patient with a history of cryptococcosis who presents with a headache should be 
treated as if he or she has recurrent disease / IRIS until proven otherwise.
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Case Study 4: Special Circumstances—
on TB Medication
Highlights drug interactions and co-infections in patients with low CD4 count
Patient history and initial presentation
A 35 year-old man is referred to an ART clinic from a TB clinic after having been diagnosed 
smear-positive for pulmonary TB 4 weeks ago. He has started on regimen 1 (RHEZ). He is 
newly diagnosed with HIV, with a CD4 count of 50.
Upon presentation to the clinic, the patient feels well, and his respiratory symptoms are 
improving. He has no headache, fever, or neck stiffness. However, upon examination, the 
patient is wasted, has crackling in his lungs, and has a red, scaly rash.
Patient management
Baseline bloods are ordered: full blood count, creatinine, ALT, and RPR 
Serum cryptococcal antigen (CrAg) test reviewed: positive 
The patient is told to complete readiness classes and return to the clinic in 2 weeks to begin 
ART.
Medication prescribed
Fluconazole 800 mg/day for 2 weeks 
Bactrim 2 tablets/day 
Vitamin B complex 2 tablets/day
Patient progress
The patient telephones the clinic 2 days later, complaining of nausea and vomiting after 
taking the fluconazole and TB medications together. The patient is asked to return to clinic for 
an ALT test, which was normal. He is advised to divide the dose of fluconazole to 400 mg two 
times per day and to take the fluconazole separately from the TB medications.  After this, the 
patient tolerates the medications well, and completes 6 months of TB treatment. 
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Case Study 4: Special Circumstances—
on TB Medication
Discussion points
1. Many patients with CD4 counts less than 100 will also have TB. Because both fluconazole 
and TB medications can damage the liver, these patients should preferably be started on 
an efavirenz-based ART regimen.
2. Fluconazole and tuberculosis can both cause liver damage so it is necessary to check for 
symptoms and signs of liver toxicity (abdominal pain, nausea/vomiting, or yellowing of 
the skin and eyes) and measure ALT if concerned.
3. Fluconazole can cause nausea/gastrointestinal problems, as can TB medications. It may 
help to split the fluconazole dose to two times per day, and if severe nausea occurs, give 
an anti-emetic 30 minutes before.
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Case Study 5: Special Circumstances—
Pregnancy
Highlights the importance of evaluating for other clinical conditions and asking for specialist 
advice when needed
Patient history and initial presentation
A 23 year-old woman, 20 weeks pregnant, is referred to your clinic. She is newly-diagnosed 
HIV-positive with a CD4 count of 42.  She reports no headache, fever, neck stiffness, or 
sensitivity to light, and there are no positive findings upon examination of the patient.
Patient management
Baseline bloods are ordered: full blood count, creatinine, ALT, and RPR
Serum cryptococcal antigen (CrAg) test reviewed: positive
Discussion Points
1. Management of a pregnant woman with incident cryptococcosis is complex and 
requires discussion with experienced specialists; this should not be undertaken lightly. 
There are several important points to consider.
a. Gestation of fetus: fluconazole can cause birth defects, especially in the first 
trimester. However, the risks of cryptococcal meningitis to the mother and fetus are so 
high that appropriate anti-fungal therapy needs to be considered.
b. Symptoms: symptomatic patients need a lumbar puncture and if positive, they 
will need amphotericin B. Asymptomatic patients should be counseled on risks and 
benefits of fluconazole therapy. 
c. Timing of ART: Even if fluconazole is not started in an asymptomatic pregnant 
patient, ART should not be delayed. However, when starting ART, one should watch 
for cryptococcal IRIS. 
d. Type of ART: the choice of ART should be made carefully. Fluconazole can interact 
with some ART medications, and this is an important consideration when  
starting ART. 
 • Nevirapine: This is the preferred regimen for pregnant patients. Fluconazole can 
cause nevirapine to build up in the body, which can increase the risk of side effects, 
specifically liver toxicity. Check for symptoms and signs of liver toxicity (abdominal 
pain, nausea/vomiting, or yellowing of the skin and eyes) and measure ALT if 
concerned.
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Case Study 5: Special Circumstances—
Pregnancy
 • Efavirenz: There are no known interactions between efavirenz and fluconazole; 
however, the use of efavirenz in pregnancy, especially in the first trimester, is not 
currently recommended.
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